Results 251 to 260 of about 12,497,887 (407)

Erratum: Developing a minimally invasive gene therapy for multiple sclerosis. [PDF]

Mol Ther Methods Clin Dev
Nijhuis PJH, Romijn M, Honing R, van Zon G, Huitinga I, de Winter F, Verhaagen J.   +6 more
europepmc   +1 more source

Targeting of gene therapy with radiation therapy

, 1992
R.R. Weichselbaum, Dennis E. Hallahan, David Gius, Vikas P. Sukhatme, Riddhi Datta, Donald Küfe   +5 more
openalex   +1 more source

Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice [PDF]

, 1998
Xiao-Qiang Qin, Nianjun Tao, Amie Dergay, Pamela Moy, Stephen E. Fawell, Alan R. Davis, James M. Wilson, James Barsoum   +7 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Gene Transfer Technology in Therapy: Current Applications and Future Goals [PDF]

, 1999
Gaetano Romano, Carmen Pacilio, Antonio Giordano   +2 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Revolutionizing Huntington's Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy. [PDF]

Cells
Gavgani PM, García-Domínguez M.
europepmc   +1 more source

Development of new virus vectors for gene therapy.

, 1994
Takashi Shimada
openalex   +2 more sources

Gene therapy clinical trials worldwide to 2017: An update

Journal of Gene Medicine, 2018
S. L. Ginn, Anais K. Amaya, I. Alexander, Michael Edelstein, M. Abedi   +4 more
semanticscholar   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source